🇺🇸 FDA
Patent

US 10709692

Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)

granted A61KA61K2121/00A61K31/422

Quick answer

US patent 10709692 (Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)) held by DENALI THERAPEUTICS INC. expires Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
DENALI THERAPEUTICS INC.
Grant date
Tue Jul 14 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 09 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
28
CPC classes
A61K, A61K2121/00, A61K31/422, A61K31/4439, A61P